Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Nicholas Wu and Meng Yuan.
Nicholas Wu
Connection Strength
2.227
Meng Yuan
  1. Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain. Nat Commun. 2021 06 21; 12(1):3815.
    View in: PubMed
    Score: 0.238
  2. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. Science. 2021 08 13; 373(6556):818-823.
    View in: PubMed
    Score: 0.237
  3. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 2020 12; 16(12):e1009089.
    View in: PubMed
    Score: 0.229
  4. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies. Biochem Biophys Res Commun. 2021 01 29; 538:192-203.
    View in: PubMed
    Score: 0.227
  5. An Alternative Binding Mode of IGHV3-53 Antibodies to the SARS-CoV-2 Receptor Binding Domain. Cell Rep. 2020 10 20; 33(3):108274.
    View in: PubMed
    Score: 0.226
  6. Structural basis of a shared antibody response to SARS-CoV-2. Science. 2020 08 28; 369(6507):1119-1123.
    View in: PubMed
    Score: 0.223
  7. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020 05 08; 368(6491):630-633.
    View in: PubMed
    Score: 0.219
  8. Homologous and heterologous serological response to the N-terminal domain of SARS-CoV-2 in humans and mice. Eur J Immunol. 2021 09; 51(9):2296-2305.
    View in: PubMed
    Score: 0.060
  9. Dynamics of B cell repertoires and emergence of cross-reactive responses in patients with different severities of COVID-19. Cell Rep. 2021 05 25; 35(8):109173.
    View in: PubMed
    Score: 0.059
  10. Diverse immunoglobulin gene usage and convergent epitope targeting in neutralizing antibody responses to SARS-CoV-2. Cell Rep. 2021 05 11; 35(6):109109.
    View in: PubMed
    Score: 0.059
  11. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection. Cell Host Microbe. 2021 05 12; 29(5):806-818.e6.
    View in: PubMed
    Score: 0.059
  12. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape. Science. 2021 02 12; 371(6530).
    View in: PubMed
    Score: 0.058
  13. Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity. Immunity. 2020 12 15; 53(6):1272-1280.e5.
    View in: PubMed
    Score: 0.057
  14. A Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model. Cell. 2020 11 12; 183(4):1058-1069.e19.
    View in: PubMed
    Score: 0.057
  15. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. Science. 2020 08 21; 369(6506):956-963.
    View in: PubMed
    Score: 0.055
  16. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.055
  17. Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections. Cell Rep. 2020 06 02; 31(9):107725.
    View in: PubMed
    Score: 0.055
  18. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill. 2020 04; 25(16).
    View in: PubMed
    Score: 0.055
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.